Acute safety and efficacy of the NeoChord procedure
OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. ME...
Saved in:
Published in | Interactive cardiovascular and thoracic surgery Vol. 20; no. 5; pp. 575 - 581 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.05.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 1569-9293 1569-9285 1569-9285 |
DOI | 10.1093/icvts/ivv014 |
Cover
Abstract | OBJECTIVES
Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach.
METHODS
Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days.
RESULTS
Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52–76) and a median EuroSCORE I of 1.9% (IQR 0.9–6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention.
CONCLUSIONS
Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients. |
---|---|
AbstractList | Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach.OBJECTIVESTransapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach.Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days.METHODSSymptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days.Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention.RESULTSBetween February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention.Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.CONCLUSIONSInitial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients. OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. METHODS Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days. RESULTS Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52–76) and a median EuroSCORE I of 1.9% (IQR 0.9–6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention. CONCLUSIONS Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients. Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days. Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention. Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients. |
Author | Manzan, Erica Aidietis, Audrius Janusauskas, Vilius Colli, Andrea Zucchetta, Fabio Rucinskas, Kestutis Zakarkaitė, Diana Gerosa, Gino |
Author_xml | – sequence: 1 givenname: Andrea surname: Colli fullname: Colli, Andrea email: colli.andrea.bcn@gmail.com organization: University of Padua – sequence: 2 givenname: Erica surname: Manzan fullname: Manzan, Erica organization: University of Padua – sequence: 3 givenname: Kestutis surname: Rucinskas fullname: Rucinskas, Kestutis organization: University of Vilnius – sequence: 4 givenname: Vilius surname: Janusauskas fullname: Janusauskas, Vilius organization: University of Vilnius – sequence: 5 givenname: Fabio surname: Zucchetta fullname: Zucchetta, Fabio organization: University of Padua – sequence: 6 givenname: Diana surname: Zakarkaitė fullname: Zakarkaitė, Diana organization: University of Vilnius – sequence: 7 givenname: Audrius surname: Aidietis fullname: Aidietis, Audrius organization: University of Vilnius – sequence: 8 givenname: Gino surname: Gerosa fullname: Gerosa, Gino organization: University of Padua |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25690455$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kL1PwzAQxS1URD9gY0bZYCDUsWM3HquKL6mCBebIsc-qURoX26nU_57QlA5IMN1J93vv6d4YDRrXAEKXGb7LsKBTq7YxTO12i7P8BI0yxkUqSMEGx13QIRqH8IFxJjDFZ2hIugPOGRshOldthCRIA3GXyEYnYIxVUu0SZ5K4guQF3GLlvE423inQrYdzdGpkHeDiMCfo_eH-bfGULl8fnxfzZaooz2KqDBGS64JJ4AqqQlDJC41nitBcaGBMVKoqqO7CRMWM4QwEIcLkUGhJOKETdNP7dsmfLYRYrm1QUNeyAdeGMuMzTnMs9ujVAW2rNehy4-1a-l3582gH3PaA8i4ED-aIZLj87rHc91j2PXY4-YUrG2W0role2vov0XUvcu3mf_svpUyGIQ |
CitedBy_id | crossref_primary_10_1161_CIRCULATIONAHA_116_024797 crossref_primary_10_1016_j_repc_2021_01_016 crossref_primary_10_1111_jocs_15350 crossref_primary_10_1161_JAHA_117_006309 crossref_primary_10_3389_fcvm_2023_1166892 crossref_primary_10_1093_icvts_ivv192 crossref_primary_10_3390_bioengineering7010025 crossref_primary_10_5847_wjem_j_1920_8642_2019_03_001 crossref_primary_10_1016_j_circv_2023_03_004 crossref_primary_10_1093_ejcts_ezx250 crossref_primary_10_1007_s00540_016_2251_9 crossref_primary_10_1097_HCO_0000000000000825 crossref_primary_10_1161_CIRCULATIONAHA_114_014023 crossref_primary_10_1213_ANE_0000000000002767 crossref_primary_10_1080_17434440_2021_1940141 crossref_primary_10_1053_j_jvca_2016_06_031 crossref_primary_10_1007_s10047_023_01383_2 crossref_primary_10_1016_j_ijcard_2018_01_049 crossref_primary_10_1111_jocs_13120 crossref_primary_10_3389_fcvm_2023_1120323 crossref_primary_10_1016_j_repce_2021_11_011 crossref_primary_10_1093_ejcts_ezz164 crossref_primary_10_1186_s12872_019_01312_3 crossref_primary_10_3389_fcvm_2022_985644 crossref_primary_10_1177_15569845231178718 crossref_primary_10_3390_ma15093302 crossref_primary_10_1177_1089253218779787 crossref_primary_10_1016_j_athoracsur_2018_01_092 crossref_primary_10_1016_j_echo_2018_01_011 crossref_primary_10_1016_j_xjon_2020_05_010 crossref_primary_10_1093_ejcts_ezz048 crossref_primary_10_3389_fcvm_2019_00088 crossref_primary_10_1016_j_medengphy_2019_09_014 crossref_primary_10_1093_ejcts_ezy046 crossref_primary_10_1007_s13239_024_00764_9 crossref_primary_10_1177_155698451801300307 crossref_primary_10_1016_j_medengphy_2022_103773 crossref_primary_10_1007_s10439_020_02464_6 crossref_primary_10_1016_j_amcp_2016_11_003 crossref_primary_10_1016_j_ijcard_2018_01_026 crossref_primary_10_1016_j_jtcvs_2020_12_142 crossref_primary_10_1111_jocs_16011 crossref_primary_10_1111_jocs_16330 crossref_primary_10_3389_fcvm_2019_00128 crossref_primary_10_1038_s41598_019_41173_6 crossref_primary_10_1093_ejcts_ezw188 crossref_primary_10_1097_imi_0000000000000506 crossref_primary_10_3390_bioengineering10050601 crossref_primary_10_1016_j_ijcard_2015_11_131 crossref_primary_10_3390_jcm11123377 crossref_primary_10_1016_j_athoracsur_2019_01_053 crossref_primary_10_1016_j_jtcvs_2020_11_105 crossref_primary_10_15420_icr_2019_13_R1 crossref_primary_10_1016_j_athoracsur_2016_05_052 |
Cites_doi | 10.1097/IMI.0b013e31816d3d08 10.1016/j.ejcts.2011.03.058 10.1016/j.jacc.2013.07.090 10.1161/hc2601.093182 10.1016/j.athoracsur.2007.03.058 10.1016/j.athoracsur.2013.09.077 10.1016/j.jcmg.2014.01.003 10.1016/j.jtcvs.2005.06.046 10.1016/j.jtcvs.2013.07.068 10.1161/01.CIR.92.4.811 10.1093/ejcts/ezs455 10.1016/j.jtcvs.2013.08.012 10.1016/j.jtcvs.2008.09.004 10.1016/j.jtcvs.2009.03.057 10.1016/j.athoracsur.2008.05.015 10.1016/j.athoracsur.2009.03.003 10.1161/CIRCIMAGING.112.000098 |
ContentType | Journal Article |
Copyright | The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. 2015 The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. |
Copyright_xml | – notice: The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. 2015 – notice: The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1093/icvts/ivv014 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1569-9285 |
EndPage | 581 |
ExternalDocumentID | 25690455 10_1093_icvts_ivv014 10.1093/icvts/ivv014 |
Genre | Journal Article Observational Study |
GroupedDBID | --- --K 0R~ 18M 1B1 29J 2WC 4.4 48X 53G 5GY AAIYJ AAJKP AAOGV AAPXW AAVAP ABKDP ABNKS ABOCM ABPTD ABQLI ABXVV ABZBJ ACGFO ACGFS ADBBV ADEYI ADHKW ADJQC ADOCK ADRIX ADRTK ADYVW ADZXQ AEGPL AEJOX AEKSI AENEX AEPUE AFOFC AFULF AFXEN AGINJ ALMA_UNASSIGNED_HOLDINGS AWCFO AXUDD BAWUL BAYMD BHONS C1A CS3 DIK DPORF DPPUQ DU5 E3Z EBD EBS EE~ EJD EMOBN F5P F9B GX1 H13 H5~ HZ~ IHE J5H KBUDW KSI M41 M~E NQ- O9- OK1 O~Y RIG RNS ROL ROX RPM RPZ RXO SEW SV3 TEU TJX TOX TR2 UHS W8F WOQ XSB ZCN AAFWJ AAYXX ABEJV ABGNP AMNDL CITATION OVT CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c361t-cf29a6d85ae6ceb893a68d07c2349de559bcb83dcac9b5ff65e9229f4e8da2623 |
IEDL.DBID | TOX |
ISSN | 1569-9293 1569-9285 |
IngestDate | Fri Jul 11 07:24:52 EDT 2025 Thu Apr 03 06:57:54 EDT 2025 Tue Jul 01 03:55:23 EDT 2025 Thu Apr 24 23:01:07 EDT 2025 Wed Sep 11 04:48:41 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Mitral valve NeoChord procedure Mitral valve repair Off-pump Regurgitation |
Language | English |
License | The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c361t-cf29a6d85ae6ceb893a68d07c2349de559bcb83dcac9b5ff65e9229f4e8da2623 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://academic.oup.com/icvts/article-pdf/20/5/575/6124816/ivv014.pdf |
PMID | 25690455 |
PQID | 1676340962 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1676340962 pubmed_primary_25690455 crossref_primary_10_1093_icvts_ivv014 crossref_citationtrail_10_1093_icvts_ivv014 oup_primary_10_1093_icvts_ivv014 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20150500 2015-05-00 2015-May 20150501 |
PublicationDateYYYYMMDD | 2015-05-01 |
PublicationDate_xml | – month: 05 year: 2015 text: 20150500 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Interactive cardiovascular and thoracic surgery |
PublicationTitleAlternate | Interact Cardiovasc Thorac Surg |
PublicationYear | 2015 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | 2015091108351374000_20.5.575.9 2015091108351374000_20.5.575.19 2015091108351374000_20.5.575.18 2015091108351374000_20.5.575.1 2015091108351374000_20.5.575.17 2015091108351374000_20.5.575.2 2015091108351374000_20.5.575.16 2015091108351374000_20.5.575.3 2015091108351374000_20.5.575.15 2015091108351374000_20.5.575.4 2015091108351374000_20.5.575.14 2015091108351374000_20.5.575.5 2015091108351374000_20.5.575.13 2015091108351374000_20.5.575.6 2015091108351374000_20.5.575.12 2015091108351374000_20.5.575.7 2015091108351374000_20.5.575.11 2015091108351374000_20.5.575.8 2015091108351374000_20.5.575.10 |
References_xml | – ident: 2015091108351374000_20.5.575.19 doi: 10.1097/IMI.0b013e31816d3d08 – ident: 2015091108351374000_20.5.575.10 doi: 10.1016/j.ejcts.2011.03.058 – ident: 2015091108351374000_20.5.575.11 doi: 10.1016/j.jacc.2013.07.090 – ident: 2015091108351374000_20.5.575.2 doi: 10.1161/hc2601.093182 – ident: 2015091108351374000_20.5.575.16 doi: 10.1016/j.athoracsur.2007.03.058 – ident: 2015091108351374000_20.5.575.17 doi: 10.1016/j.athoracsur.2013.09.077 – ident: 2015091108351374000_20.5.575.7 doi: 10.1016/j.jcmg.2014.01.003 – ident: 2015091108351374000_20.5.575.5 doi: 10.1016/j.jtcvs.2005.06.046 – ident: 2015091108351374000_20.5.575.18 doi: 10.1016/j.jtcvs.2013.07.068 – ident: 2015091108351374000_20.5.575.15 doi: 10.1161/01.CIR.92.4.811 – ident: 2015091108351374000_20.5.575.1 doi: 10.1093/ejcts/ezs455 – ident: 2015091108351374000_20.5.575.12 doi: 10.1016/j.jtcvs.2013.08.012 – ident: 2015091108351374000_20.5.575.4 – ident: 2015091108351374000_20.5.575.8 doi: 10.1016/j.jtcvs.2008.09.004 – ident: 2015091108351374000_20.5.575.9 doi: 10.1016/j.jtcvs.2009.03.057 – ident: 2015091108351374000_20.5.575.3 doi: 10.1016/j.athoracsur.2008.05.015 – ident: 2015091108351374000_20.5.575.6 doi: 10.1016/j.athoracsur.2009.03.003 – ident: 2015091108351374000_20.5.575.13 – ident: 2015091108351374000_20.5.575.14 doi: 10.1161/CIRCIMAGING.112.000098 |
SSID | ssj0019030 |
Score | 2.3095338 |
Snippet | OBJECTIVES
Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This... Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 575 |
SubjectTerms | Aged Cardiac Catheterization - methods Chordae Tendineae - surgery Cohort Studies Echocardiography, Transesophageal - methods Feasibility Studies Female Follow-Up Studies Heart Valve Prosthesis Heart Valve Prosthesis Implantation - methods Hospitals, University Humans Italy Length of Stay Male Middle Aged Minimally Invasive Surgical Procedures - methods Mitral Valve Insufficiency - diagnostic imaging Mitral Valve Insufficiency - physiopathology Mitral Valve Insufficiency - surgery Patient Safety Postoperative Complications - physiopathology Prospective Studies Prosthesis Design Prosthesis Failure Treatment Outcome |
Title | Acute safety and efficacy of the NeoChord procedure |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25690455 https://www.proquest.com/docview/1676340962 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La8MwDDajp13Gxl7dCw-20wht7cSxj6VslMG6Swu9BcdWWGEko0kK_feTnbTQPeglJ8XGsvD3ybIkQh7QaiQwV09bAH4Yg8ClbwbAJdMytSL0d7pvEzGeha_zaN4WSSr_COEr3luYVVX2FqtV3zesRvx19jx9n2-jBarve4qgK6IChHvePnD_-fMO9Oyks_1ilR5dXo7JUUsL6bDZxxNyAPkp4UNTV0BLnUG1pujyU3AFH7RZ0yKjyNzoBIrRB7qP1OOQrZdwRmYvz9PROGibHASGi0EVmIwpLayMNAgDKdIHLaTtx4bxUFlAwp-aVHKLg6s0yjIRgWJMZSFIqxmSl3PSyYscLgllWRTGsbJSu3s99HuN1pGWKlYunRZ4lzxt1p-YtgK4a0TxmTSRaJ54bSWNtrrkcSv91VS--EeOoir3iNxv9Jyg9bqQhM6hqMtkIPB8Q3MQrEsumg3YjoRkTCHhjK72T3BNDplLS_AP825Ip1rWcItkoUrvvKV8A2CsvNA |
linkProvider | Oxford University Press |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+safety+and+efficacy+of+the+NeoChord+procedure&rft.jtitle=Interactive+cardiovascular+and+thoracic+surgery&rft.au=Colli%2C+Andrea&rft.au=Manzan%2C+Erica&rft.au=Rucinskas%2C+Kestutis&rft.au=Janusauskas%2C+Vilius&rft.date=2015-05-01&rft.pub=Oxford+University+Press&rft.issn=1569-9293&rft.eissn=1569-9285&rft.volume=20&rft.issue=5&rft.spage=575&rft.epage=581&rft_id=info:doi/10.1093%2Ficvts%2Fivv014&rft.externalDocID=10.1093%2Ficvts%2Fivv014 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-9293&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-9293&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-9293&client=summon |